Research & Development Pipeline

Complement and Thyroid Core Assets Advancing with Clear Differentiation

  • EA5, as our core clinical asset, has completed pivotal registration preparation for PNH indication, targeting commercialization by 2028.
    Key Update
    EA5, as our core clinical asset, has completed pivotal registration preparation for PNH indication, targeting commercialization by 2028.
描述
Company Name：Neathera Inc.
Email：info@neathera.com
描述
CONTACT US
NAVIGATION
Copyright © 2019-2026 Neathera Inc. All rights reserved.